High-density lipoprotein infusion therapy for heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. KU Leuven
Heart failure (HF) is a growing public health problem, the leading cause of hospitalization, and a major cause of mortality. Approximately 50% of chronic HF patients have HF with reduced ejection fraction (HFrEF) and 50% suffer from HF with preserved ejection fraction (HFpEF). As the population ages, HFpEF will continue to be a growing public health problem. In contrast to advances in the treatment of patients with HFrEF, drug strategies with ...